Related Experiment Video
Updated: May 30, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Circulating T cells fuel anti-PD-1 and lenvatinib efficacy
Peter J Matulich1, Megan L Burger2
1Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Researchers identified a specific CD8+ T cell population crucial for the effectiveness of combined immunotherapy and anti-angiogenic treatments in liver cancer. Targeting these cells may improve cancer immunotherapy outcomes in various settings.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Synergy between immune checkpoint blockade and anti-angiogenic therapy is not fully understood.
- Hepatocellular carcinoma (HCC) treatment often involves combination therapies.
Purpose of the Study:
- To elucidate the mechanisms behind the synergistic effects of anti-PD-1 and lenvatinib in HCC.
- To identify specific immune cell populations involved in treatment response.
Main Methods:
- Analysis of hepatocellular carcinoma patients treated with anti-PD-1 and lenvatinib.
- Identification and characterization of circulating immune cells.
Main Results:
- A distinct circulating CD8+ T cell population was identified as critical for treatment efficacy.
- This T cell population plays a key role in the response to combined immunotherapy and anti-angiogenic therapy.
Conclusions:
- The identified CD8+ T cell population is a potential biomarker for treatment response in HCC.
- Targeting this specific T cell population could enhance the efficacy of immunotherapy in various cancer types.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
